Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1996-2-16
|
pubmed:abstractText |
The effect of VLDL on plasminogen activator inhibitor type 1 biosynthesis in HepG2 cells was investigated. Exposure of HepG2 cells to VLDL (range, 10 to 100 micrograms protein per milliliter) for 16 hours resulted in an enhanced release of PAI-1 antigen and PAI activity into conditioned medium, accompanied by the accumulation of intracellular triglycerides. By using a monoclonal antibody (IgG C7) specific to the LDL receptor, we showed that the effect of VLDL is mediated by its interaction with the LDL receptor. Enhanced PAI-1 release was due to increased biosynthesis: PAI-1 mRNA was doubled, mainly because of the effect on the 2.2-kb PAI-1 mRNA rather than the 3.2-kb transcript. Addition of insulin with the VLDL further enhanced PAI-1 antigen release and PAI-1 mRNA accumulation. The effect of VLDL on steady state levels of PAI-1 mRNA was apparently not due to an increase of gene transcription but to stabilization of both PAI-1 mRNA transcripts. The enhancing effect of VLDL on PAI-1 biosynthesis in HepG2 cells may raise PAI-1 antigen levels not only in hypertriglyceridemic states but also in those conditions in which both insulin and VLDL are elevated.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Culture Media, Conditioned,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins, VLDL,
http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen Activator Inhibitor 1,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1079-5642
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
16
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
89-96
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8548432-Carcinoma, Hepatocellular,
pubmed-meshheading:8548432-Culture Media, Conditioned,
pubmed-meshheading:8548432-Gene Expression Regulation,
pubmed-meshheading:8548432-Humans,
pubmed-meshheading:8548432-Lipoproteins, VLDL,
pubmed-meshheading:8548432-Liver Neoplasms,
pubmed-meshheading:8548432-Plasminogen Activator Inhibitor 1,
pubmed-meshheading:8548432-RNA, Messenger,
pubmed-meshheading:8548432-Receptors, LDL,
pubmed-meshheading:8548432-Triglycerides,
pubmed-meshheading:8548432-Tumor Cells, Cultured
|
pubmed:year |
1996
|
pubmed:articleTitle |
Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL.
|
pubmed:affiliation |
Institute of Pharmacological Sciences and E. Grossi Paoletti Center, University of Milan, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|